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ABSTRACT
Slow reconstitution of the T cell repertoire after allogeneic blood or bone marrow stem cell transplantation is
a major risk factor for patient mortality. The delivery of immunocompetent T cells as delayed donor lymphocyte
infusions (DLIs) is a potential way of counteracting this problem. The development of graft-versus-host disease
(GVHD) is a potential complication of this procedure, however. We previously found that in P/F1 haploident-
ical murine models, the ex-vivo treatment of donor lymphocytes with L-leucyl-L-leucine methyl ester (LLME)
can prevent the onset of GVHD after DLI, likely by inducing cell death in most of the perforin-positive CD81T
cells and in a fraction of CD41Tcells. Our previous preclinical studies have formed the basis of an ongoing phase
I clinical trial in which patients received LLME-treatedDLI from their original donor in an attempt to accelerate
T cell reconstitution. To understand how this treatment strategy might affect the complexity of the DLI T cell
repertoire, we used T cell receptor Vb spectratype analysis to evaluate the DLI product pre-LLME and post-
LLME treatment. The results indicated that the LLME-treated DLI product exhibited CDR3-size distribution
complexities similar to those of its untreated donor sample. In addition, comparisons of the CD41 and CD81T
cell repertoire from the donor before LLME treatment with that of the recipient post-DLI demonstrated equal
complexity for most of the resolvable Vb families. Finally, the in vitro proliferative capacity of LLME-treated
DLI product in response to allo-stimulation in a one-way mixed lymphocyte reaction was comparable to that
of the untreated product.
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analysisINTRODUCTION
Delayed and/or incomplete T cell reconstitution
and the correlating lack of graft-versus-leukemia
(GVL) effects and opportunistic infections after allo-
geneic blood or bone marrow transplantation (BMT)
are major risk factors for patient morbidity and mortal-
ity. This is particularly true in the case of CD34-
enriched, T cell–depleted hematopoietic stem cell
transplantation (HSCT), where, to avoid the develop-
ment of acute graft-versus-host disease (GVHD), no
immediate source of mature donor T cells is provided
[1]. Thus, immune reconstitution in this situation de-
pends solely on the ability to generate de novo T cells
via the host thymus, which may have limited functionalcapabilities in these patients [2]. One approach to rec-
tifying this problem of T cell reconstitution is to ad-
minister immunocompetent T cells in the form of
a delayed donor lymphocyte infusion (DLI) 1-3
months posttransplantation, with the intent of provid-
ing the lymphocytes in the setting of an environment
with diminished host inflammatory responses associ-
ated with the pretransplantation conditioning regimen
[3,4]. Nevertheless, DLI’s effective reconstitution po-
tential is seriously hampered by the development of
GVHD [5-7], and these opposing effects need to be
separated by some means.
In this regard, several murine studies have indi-
cated that both the CD4 and CD8 T cells that mediate1439
1440 T. M. Friedman et al.GVHD immunopathology depend on the utilization
of perforin cytolytic mechanisms [8,9]. In addition,
immunohistochemical studies of epidermal tissue
from transplantation recipients have correlated acute
GVHD lesions with the presence of perforin-contain-
ing cytolytic T cells [10,11]. In contrast, investigation
of GVL mechanisms in some myeloid leukemia
models have found significant CD4-mediated GVL
potential in the absence of perforin pathways [12,13]
and the transfer of monoclonal populations of tu-
mor-specific CD41 versus CD81 T cells were more
efficient at tumor rejection when tested against several
different tumor lines [14]. Thus, elimination of per-
forin-positive T cells from DLI inoculum could be
a means of separating GVHD and GVL responses,
and may allow for rapid reconstitution of immune
capabilities in BMT recipients.
L-leucyl-L-leucine methyl ester (LLME) is a lyso-
somotropic agent that acts preferentially on cells con-
taining dipeptidyl peptidase I enzymes in their
cytolytic granules, which normally also contain per-
forin [15]. The overall effect is to induce cell death
of most natural killer (NK) cells, monocytes, granulo-
cytes, and CD81 T cells and a small fraction of CD41
T cells. LLME has been used previously to treat hema-
topoietic cell grafts in an effort to reduce the occur-
rence of GVHD in both murine and canine models
[16-18]. However, its use as GVHD prophylaxis in
human BMT was abandoned when clinical trials
indicated that the effective concentration required
for the ex vivo elimination of GVHD-reactive T cells
from marrow inoculum resulted in engraftment failure
[19]. Thus, we considered the possibility that LLME
could still be used as an immunomodulating agent
for BMT if used to eliminate perforin-positive allor-
eactive T cells from a separate DLI product adminis-
tered after T cell–depleted HSCT.
In preclinical experiments using a haploidentical
murine model, lethally irradiated (B6x DBA/2) mice
were transplanted with T cell–depleted B6 bone mar-
row at day 0, then injected with mock- or LLME-
treated B6 DLI at day 14 posttransplantation and
monitored for symptoms of GVHD and immune re-
constitution. All mice receiving mock-treated DLI
succumbed to acute GVHD, whereas those injected
with LLME-treated DLI exhibited no signs of disease
(with 100% survival) and demonstrated immune re-
constitution comparable to that of normal B6 mice
by 10 weeks posttransplantation [8].
These preclinical studies formed the basis of an on-
going phase I clinical trial in which patients received
LLME-treated DLI from their original donor in an
attempt to accelerate T cell reconstitution after
CD34-enriched allogeneic peripheral blood stem cell
transplantation. Donors were HLA-identical siblings,
HLA-identical, or single-antigen mismatched unre-
lated donors or mismatched (haploidentical) relateddonors. The results of this clinical study are fully de-
scribed elsewhere (Filicko et al., submitted for publica-
tion), but an important question was raised as to
whether this LLME treatment strategy might affect
the complexity of the DLI T cell repertoire being in-
fused into patients, thereby affecting their reconstitu-
tion potential. This is particularly relevant to the
CD8 subset, which has been recently reported to con-
tain between 5 and 9 discrete subpopulations, each of
which was observed to express different levels of per-
forin in addition to being represented in different pro-
portions among individuals [20,21]. Taken together
with its mechanism of action, LLME treatment of
the DLI thus could potentially create major deficits
in the repertoire within the different Vb families. To
address this issue, we used T cell receptor (TCR) Vb
CDR3-size spectratype analysis to evaluate the DLI
product, pre-LLME and post-LLME treatment,
from peripheral blood mononuclear cells (PBMCs)
of 6 donor–patient pairs. PBMC cells obtained from
donors at the time of DLI donation, before LLME
treatment, served as the baseline spectratype for Vb
complexity. Thus, the CD41 and CD81 T cell reper-
toire complexity of each LLME-treated DLI product
was determined through comparison to its untreated
sample.
The results of the spectratype analysis indicated
that overall, the LLME-treated DLI products ex-
hibited CDR3-size distribution complexities similar
to those of the untreated donor sample for the resolv-
able Vb families. In addition, we were also able to
examine the complexity of the posttransplantation
CD41 and CD81 T cell repertoires in 4 of the 6 pa-
tients and found that both subsets exhibited reconsti-
tution complexities similar to those of the DLI
donor samples for the resolvable Vb families. Finally,
we found the in vitro proliferative capacities of
LLME-treated PBMCs in response to allostimulation
in a 1-way mixed lymphocyte reaction (MLR) to be
comparable to that of untreated PBMCs. In summary,
it appears that ex vivo LLME treatment of DLI does
not adversely affect the complexity or functional ca-
pacity of the T cell repertoire, and thus this transplan-
tation strategy is likely to afford advantages with
regard to rapid immune reconstitution.
MATERIALS AND METHODS
Patients and Donors
Twenty-three patients with hematologic malig-
nancies at Thomas Jefferson University or the Medical
College of Wisconsin who underwent CD34-enriched
HSCT were enrolled in the study. Ten patients had
HLA-identical sibling donors, 8 had unrelated donors
(4 HLA-matched, 4 mismatched), and 5 had haplodis-
parate donors. Three patients died before receiving
DLI. One patient received unmanipulated DLI, and
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Eighteen patients, age 6-65 years (median, 47 years)
received LLME DLI as originally planned, including
various preparative regimens. The 6 patients discussed
herein received CD34-selected HSCT after fludara-
bine, cytarabine, and melphalan (FAM) 1 antithymo-
cyte globulin (ATG) (Thymoglobulin; SangStat) as
described previously [22].
Prophylactic antibiotics consisted of an amphoter-
icin product, valacyclovir, and trimethoprim-sulfame-
thoxazole in all patients. All patients received
transfusion support with leukodepleted and irradiated
cellular blood products. Patients who were cytomega-
lovirus-seronegative received cytomegalovirus-sero-
negative blood products. Patients were followed with
weekly ATG levels and were eligible to receive
LLME DLI when the ATG level was\ 2.0 mg/mL.
LLME Treatment
LLME was synthesized under GMP conditions by
Bachem (Switzerland). LLME dry powder was pre-
pared in Normosol R at a 500 mmol concentration.
Washed cells (blood or apheresis product) were incu-
bated with LLME at a concentration of 10  106
cells/mL for 60 min. Cells were washed in Normosol
(4C  1, then room temperature  2). Release crite-
rion for the LLME-treated products was 80% deple-
tion of NK cells (CD16/561, CD3). Samples of the
cells were labeled with fluorescein isothiocyanate–
conjugated anti-CD4, anti-CD8, anti-CD16, or CD56
monoclonal antibodies, or phycoerythrin (PE)-conju-
gated anti-CD3 antibodies, and then analyzed by flow
cytometry with a FACScan (Becton Dickinson, Finger
Lakes, NJ). Patients received LLME-treated DLI,
based on viable CD31 cell counts.
Blood Samples
PBMCs were enriched from donor and patient pe-
ripheral blood samples, as described previously [23],
by centrifugation over Ficoll-Histopaque (Sigma, St
Louis, MO). CD41 and CD81T cell subsets were sep-
arated by standard antibody-panning techniques, and
the enriched subset populations were solubilized in
Ultraspec (Biotex Laboratories, Houston, TX). The
single exception was the LLME-treated DLI product
from patient 5, which remained unseparated. Vb spec-
tratype analysis of separated PBMCs from untreated
donor samples served as the reference point for full
repertoire complexity, and was used as the standard
of comparison for the LLME-treated, as well as post-
transplantation, samples. At the time of the posttrans-
plantation spectratype analysis, all patients exhibited
.90% donor chimerism, as determined by molecular
analysis of short tandem repeats of marrow or
PBMC samples [24].CDR3-Size Spectratype Analysis
Total RNA was isolated from Ultraspec samples,
and cDNA was prepared as described previously [23].
Semi-nested polymerase chain reaction was performed
using a panel of human Vb sense oligoprimers and 2
Cb antisense oligoprimers; the second Cb being fluo-
rescently labeled [23]. The polymerase chain reaction
products were run on a sequencing gel and analyzed
using Genotyper Genescan software (Applied Biosys-
tems, Foster City, CA). This approach allowed direct
comparison of the Vb repertoire complexity in the
pre-LLME and post-LLME DLI products.
Spectratype Complexity Index
The complexity index within a Vb family was de-
termined as a percentage of the number of peaks found
in its spectratype histogram in relation to the number
of peaks in the corresponding donor Vb family histo-
gram, as described previously [23]. Any Vb family
with a complexity index of$85% was considered fully
complex. Histogram peaks were identified by Geno-
typer Genescan. For some of the donor/patient sam-
ples, several Vb families in the untreated DLI
product did not exhibit an evaluable spectratype, but
the LLME-treated product did. In these cases, we
compared the number of peaks to the average number
of peaks for that particular Vb family obtained from
the other samples; any donor or patient sample exhib-
iting fewer than 12 evaluable Vb family spectratypes
was excluded.
Statistical Analysis
Data comparisons were analyzed by nonparamet-
ric Wilcoxon’s rank-sum analysis. P values # .05
were considered statistically significant.
MLR Assay
LLME- and mock-treated PBMCs from 4 healthy
volunteers were cultured at 1  105 cells/well with ir-
radiated (30 Gy) PBMCs from a fifth healthy volunteer
in 96-well tissue culture plates, at a 1:2 responder:sti-
mulator ratio. Proliferative responses were determined
after 6 days in culture (37C; 8% CO2) by measuring
H3-thymidine (1 mCi/well) incorporation after a 6-
hour pulse/label period. Quadruplicate samples were
used to determine the mean incorporation counts per
minute on a 1205 Betaplate liquid scintillation counter
(Perkin-Elmer, Gaithersburg, MD).
RESULTS
Patient Characteristics and GVHD Status
The age, gender, underlying diseases, and trans-
plantation characteristics of the 6 patients are given
in Table 1. All patients underwent CD34-selected
HSCT after fludarabine, cytarabine, and melphalan
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Patient Age (years)/sex Disease Graft type DLI dose/kg GVHD
Post-DLI
sample day
Days Post-CD34
HSCTof DLI
1 61/M ALL, CR1 Maternal sibling 1  107 None 64 43
2 38/M ALL, first relapse Haplo-M NA NA NA NA
3 22/M CML (LBP, CR1) Maternal sibling 1  106 None 49 101
4 53/M CML, accelerated
phase
Maternal sibling First: 1  107 Grade III 42 First: 27
Second: 4  107 Second: 70
5 19/M ALL, CR2 URD 1  105 None 329 118
6 52/F AML, CR1 Maternal sibling 1  107 None 68 70
Median patient age was 45 years (range, 19-61 years). Four patients received transplants from HLA-identical sibling donors (maternal sibling);
1 patient, from a completely matched (10/10) unrelated donor (URD); and 1 patient, from a haplodisparate maternal donor (Haplo-M).(FAM) 1 antithymocyte globulin (ATG). One patient
developed grade III GVHD after a second dose of
LLME DLI. This patient had received an initial
dose of 1  107 LLME-treated DLI, but had not
reached the target of 200 CD41 cells/mL, and thus re-
ceived a second LLME-treated DLI 43 days later. One
week after the second dose of LLME DLI, at 4.1 107
CD31 cells/kg (target, 1  108 cells/kg), this patient
developed GVHD of the skin and gastrointestinal
tract. None of the other patients developed GVHD.
One patient expired after relapse of her AML 175
days after LLME DLI. One patient required high-
dose steroid therapy for interstitial pneumonitis and
subsequently expired due to multisystem organ failure
related to sepsis. The 1 patient who did develop
GVHD was treated with immunosuppressive therapy,
including high-dose steroids, and subsequently suc-
cumbed secondary to complications of infection. The
other 3 are alive at the time of this writing, with no ev-
idence of GVHD, opportunistic infection or relapse of
their leukemia, at 1399, 1029, and 620 days post-
LLME DLI.
Determination of Complexity Index after LLME
Treatment
LLME is known to cause rapid apoptosis of per-
forin- and granzyme-containing cells, thereby affect-
ing most NK cells, macrophages, and CD81 T cells,
along with a small subset of CD41 T cells. However,
due to the differential expression of perforin, particu-
larly within the CD8 subpopulations, we evaluated
whether LLME treatment of the DLI product might
affect the complexity of the overall T cell repertoire.
CDR3-size spectratype analysis was used to compare
the complexity of 24 Vb families in the CD4 and
CD8 T cell subsets from the DLI products before
and after LLME treatment. Spectratype histograms
of the pre– and post–LLME-treated donor CD41 T
cells for 3 representative Vb families from each of
five patients are shown in Figure 1. The complexity in-
dex for the Vb families was determined, as described in
Materials and Methods, by comparing the donor pre-LLME and post-LLME treatment spectratype histo-
grams. The results, summarized in Tables 2 and 3
for the evaluable patients and Vb families, show overall
complexity indices for the CD4 and CD8 compart-
ments of 82.7% (Standard error of the mean [SEM]5
6.2%) and 79.6% (SEM 5 6.2%), respectively. There
was no statistical difference (P $ .68) between the
overall complexity of the CD41 and CD81T cell sub-
sets, suggesting that LLME treatment did not cause
biased apoptosis of any particular Vb family in either
subset, even though there was a much greater deple-
tion (P 5 .001) of CD31/CD81 cells (mean, 60.9%;
range, 35.1%-81.9%) than CD31/CD41 cells (mean,
27.5%; range, 0-53%) by LLME.
Donor Chimerism and Flow Cytometric Analysis
During the peritransplantation period after infu-
sion of the CD34-enriched stem cell graft, all patients
received ATG as part of GVHD prophylaxis. Patients
were subsequently eligible to receive LLME-treated
DLI when the serum ATG level was\2 mg/mL. Mo-
lecular analysis performed on bone marrow or PBMCs
indicated nearly complete T cell donor chimerism
(. 90%) for the 5 evaluable patients at the time of sam-
ple collection for spectratype analysis. Furthermore,
PBMCs were collected from these 5 patients on a reg-
ular basis post-DLI, and flow cytometry analysis was
performed to evaluate the overall T cell reconstitution.
One patient never recovered a CD3/CD41 cell count
.25/mL. The other five patients achieved a CD31/
CD41 count .100 /mL (median, 163.9/mL; range,
115.31–471.0/mL) at a median of 34 days post-DLI.
This was associated with a robust CD31/CD81 recov-
ery (median, 608.8/mL; range, 225.81-2304.96/mL).
Determination of Complexity Index after DLI
Infusion
To identify any significant differences in the com-
plexity of the reconstituting CD41 and CD81 T cell
subsets, CDR3-size spectratype analysis was used to
analyze PBMC samples from the evaluable patients
Conservation of T Cell Repertoire Complexity after LLME Treatment of DLI 1443Figure 1. CDR3-size spectratype analysis of PBMCs enriched from the DLI products of 5 donors before and after LLME
treatment. The spectratype analysis was performed as described in Materials and Methods. Three representative Vb spec-
tratypes are shown for each donor.after infusion of the LLME-treated DLI product.
Spectratype histograms of the donor LLME-treated
CD41T cell DLI product and the posttransplantation
sample for a representative Vb family from each of 3
Table 2. CD41 repertoire complexity analysis
Patient
Vb 1 2 3 4 5 6
1 1 1 1 1 (1) 1
2 1 1 1 1 (1) 1*
3 1 1 1 1 (1) 1
4 1 ND ND 1 (1) ND
5 1 1 1 1 (1) 1*
6 1 ND 1 ND ND ND
7 1 2 1 1 (1) ND
8 1 ND 1 1 (1) 2
9 1 1 1 1 (1) 1
10 1 ND ND 2 ND ND
11 1 1 1 ND (1) 1*
12 2 ND ND 1 (1) ND
13 1 2 1 2 (1) 2*
14 1 1 1 2 (1) 2*
15 1 1 1 1 (1) 1
16 1 2 1 1 (2) 2*
17 1 1 1 1 (1) 1
18 1 2 1 1 (1) ND
19 2 2 1 1 (1) ND
20 ND 1 ND 1 ND 2*
21 1 2 1 1 (1) ND
22 1 ND ND 2 ND ND
23 1 1 1 1 (1) ND
24 2 ND ND ND ND ND
Overall complexity 87% 65% 100% 85% 95% 64%
2 indicates non-full complexity; 1 indicates full complexity.
(), CD4 and CD8 subsets not separated.
ND, not determined.
*Complexity compared with averaged control donors.patients are given in Figure 2. All 3 histograms show
no significant differences in the overall level of Vb fam-
ily complexity between the 2 samples. In regard to all
of the data sets, although some individual Vb family
Table 3. CD81 repertoire complexity analysis
Patient
Vb 1 3 4 5 6
1 1 2 2 (1) 1
2 1 1 2 (1) 1
3 1 1 1 (1) 1
4 1 1* 2 (2) 1
5 1 1 1 (1) 1
6 1 1 2 ND ND
7 1 1 1 (1) 1
8 1 1 1 (1) 1
9 1 1 1 (1) 1
10 1 ND 1 ND ND
11 1 1 1 (1) 1
12 2 ND ND ND ND
13 2 1 2 (1) 1
14 1 1 1 (2) 1
15 1 1 ND (1) 1
16 1 2 ND (2) 1
17 1 1* 2 (1) 1
18 1 2 ND (1) 2
19 1 ND 1 (1) 1
20 ND ND ND ND 2
21 1 2 1 (1) 1
22 1 ND 2 ND ND
23 2 1 ND (1) 1
24 ND ND ND ND ND
Overall complexity 86% 78% 56% 89% 89%
2 indicates non-full complexity; 1 indicates full complexity.
(), CD4 and CD8 subsets not separated.
ND, not determined.
*Complexity compared with averaged control donors.
1444 T. M. Friedman et al.differences between a donor LLME-DLI sample and
the posttransplantation patient sample were seen, the
results for the 4 evaluable patients indicated mean
overall complexity indices of 75% (SEM 5 5.5%;
Table 4) for the CD4 compartment and 80%
(SEM 5 3.5%; Table 5) for the CD8 compartment.
In addition for both T cell subsets, there were no
significant differences in the overall complexity indices
(P $ .29, CD4; P . .71, CD8) between the LLME-
DLI products at the time of infusion and posttrans-
plantation. Furthermore, there was also no statistical
difference between the overall complexity indices of
the CD4 and CD8 compartments in the reconstituting
repertoires (P . .68). Taken together, these results
suggest that LLME-treated DLI did not appear to un-
dergo any biased reconstitution with regard to the
complexity of the recovering subsets.
Proliferative Capacity of LLME-Treated
Lymphocytes
We used an in vitro one-way MLR assay to evalu-
ate the proliferative capacity of LLME-treated
PBMCs in response to allostimulation. Responder
PBMCs from 4 healthy donors were mock- or
LLME-treated according to the protocol described
above for patient sets, and then plated in a 96-well
Figure 2. CDR3-size spectratype analysis of CD41 T cells enriched
from PBMCs of 3 patients after receiving LLME-treated DLI. The
spectratype analysis was performed as described in Materials and
Methods. A representative Vb spectratype is shown for each patient
comparing the LLME-treated DLI with the reconstituting patient
repertoire posttransplantation.plate along with irradiated (30 Gy) PBMC stimulators
from a fifth HLA-disparate healthy donor. Prolifera-
tive responses were determined after 6 days by measur-
ing H3-thymidine incorporation after a 6-h pulse/label
(1 mCi/well) period using unstimulated responder cells
as the baseline. The mock-treated and LLME-treated
samples exhibited a 50-fold (range, 31- to 84-fold; me-
dian, 41-fold) and 56-fold (range, 49-62; median, 56)
increase in proliferation, respectively, with no sig-
nificant difference between the 2 groups (P . .67;
Figure 3). These results suggest that the in vitro
proliferative capacity of PBMCs in response to allo-
stimulation is maintained after LLME treatment.
DISCUSSION
Rapid recovery of a functional immune system af-
ter allogeneic BMT is essential for its long-term suc-
cess as an enduring treatment for hematopoietic
malignancies. Delayed immune reconstitution is
largely responsible for the elevated levels of morbidity
and mortality associated with the peritransplantation
period [25,26]. T cell reconstitution is a vital part of
this process. One potential mechanism used for regen-
eration of the T cell repertoire consists of de novo
expansion of thymic-derived T cells generated from
Table 4. CD41 Posttransplantation complexity analysis
Patient
Vb 1 3 4 5
1 - 1 1 1
2 1 1 2 1
3 1 1 1 1
4 1 1* 1* 1
5 2 1 2 1
6 2 1 1* 1
7 2 1 2 1
8 1 1 2 1
9 1 1 2 1
10 ND 1* 1* 1
11 1 1 1* 1
12 ND 2* ND ND
13 2 1 1 2
14 1 1 2 2
15 2 1 2 1
16 1 1 1 1
17 1 1 2 1
18 1 1 1* 1
19 2 1 1 2
20 ND ND 1 ND
21 1 2 1 1
22 2 1* 1 ND
23 2 1 1 1
24 1 1* 1* ND
Overall complexity 57% 92% 65% 85%
2 indicates non-full complexity; 1 indicates full complexity.
ND, not determined.
*Complexity compared with averaged control donors.
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route of repertoire regeneration is confounded by
both the delayed time frame in which T cell matura-
tion and selection occurs, the diminished functional
Table 5. CD81 Posttransplantation complexity analysis
Patient
Vb 1 3 4 5
1 2 ND 1 1
2 1 ND 2 1
3 1 ND 2 1
4 1 1 2 1
5 2 ND 2 1
6 1 1 1 1*
7 2 1 1 1
8 1 1 1* 1
9 2 1 1 1
10 ND 1* 1 2
11 1 1 1 1
12 1 1* ND 1*
13 1 1 1 2
14 2 2 1 2
15 2 1 1* 1
16 1 1 1* 1
17 1 ND ND 1
18 2 1 1* 1
19 1 1* 1 2
20 ND ND ND 2*
21 1 1 1 1
22 ND 1* 1 1*
23 1 2 1* 1
24 ND ND ND ND
Overall complexity 65% 88% 80% 87%
2 indicates non-full complexity; 1 indicates full complexity.
ND, not determined.
*Complexity compared with averaged control donors.
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Figure 3. Proliferative responses of mock- or LLME-treated
PBMCs. The immunocompetency of mock- and LLME-treated
PBMCs from 4 individuals was assessed in vitro by measuring
[3H]-TdR incorporation in response to allostimulation.capacity of an oftentimes involuted thymus of an older
patient, and subsequent chemotherapy and radiation
induced damage to the organ [28].
An alternative route for the regeneration of im-
mune competency would then consist of transplanting
exogenous T cells as part of the donor inoculum or as
a DLI. Homeostatic mechanisms may allow these ma-
ture T cells (particularly CD81 T cells) to expand in
vivo and repopulate the lymphoid organs [29]. The
major caveat of this approach is, of course, the compli-
cation of GVHD, which cannot be easily controlled
without diminishing the T cell response capacity nec-
essary for GVL effects and protection from opportu-
nistic infections [5].
Experimental mouse transplantation models have
suggested that GVHD, in contrast to GVL effects,
may be preferentially mediated by perforin-positive
T cells to a great extent [5,6,30]. Several studies have
examined the outcome of pan-CD81 T-cell depletion
of the allograft before its administration as DLI, and
whereas decreases in the incidence of GVHD have
been reported, less information is available regarding
retention of GVL activity and the ability to mount im-
mune responses to opportunistic infections [31,32].
LLME treatment of the DLI differs from pan-CD8
depletion in that it uses a mechanistic pathway that
also is likely to deplete any perforin-positive CD41
T cells that could be involved in potentiating GVHD
[33]. Conversely, any remaining perforin-low or -neg-
ative CD81 T cells [32] still would be available to
mount GVL responses through other cytolytic mech-
anisms, such as fas-ligand or TRAIL interactions [34-
38], and still would be able to respond to antigenic
stimulation with cytokine production, particularly
interferon-g, which can enhance inflammatory re-
sponses against the tumor cells. Syngeneic and HLA-
matched sibling transplants performed by the Center
for International blood and Marrow Transplant Re-
search have demonstrated convincing evidence of
GVL effects for leukemia patients who had no clinical
evidence of GVHD [39]. This demonstrates clearly in
man that although these 2 phenomena may overlap, it
is possible to preserve/demonstrate GVL responses in
the absence of GVHD. The clinical goal is to convert
the other patients (those who have GVHD) into pa-
tients with no (or at least less) GVHD while retaining
some GVL effects for them. The goal of numerous
preclinical and clinical investigations has been to try
to reduce GVHD potential to a greater degree than
GVL capability through pharmacoprophylaxis or
depletion of 1 or another T cell subpopulation. Con-
sistent with this aim, selective depletion of perforin-
positive T cells with LLME might allow for reduced
GVHD risk with retention of GVL responses and pro-
tection from opportunistic infection, while also allow-
ing for the increased reconstitution of the CD41T cell
compartment. Whether depletion of perforin-positive
1446 T. M. Friedman et al.T cells will accomplish this goal can be ascertained
only after completion of this trial.
The reestablishment of immunocompetency
would likely be dependent on regenerating the diver-
sity and complexity of the T cell repertoire. Toward
this end, the demonstration that LLME treatment of
the DLI product did not cause or induce any biased de-
pletion of any TCR specificities is of major importance
in the successful use of this treatment in the clinic. Be-
yond the maintenance of a complex repertoire, the
functional capability of the DLI product in response
to antigen stimulation is an important consideration.
The LLME-treated DLI was shown to be capable of
eliciting proliferative responses in vitro, with major
histocompatibility complex alloreactivity as an exam-
ple. In this regard, we would hypothesize that in addi-
tion to response capability to any potential antigen,
LLME-treated DLI also can still respond to minor
HA or major histocompatibility complex alloantigens
presented in the patient. Despite this retention of pro-
liferative capacity, GVHD pathological development
is diminished because of the lack of perforin-contain-
ing effector cells. In addition, we also observed that af-
ter LLME, there was a rapid reconstitution of the
CD41 and CD81 T cell subsets. This reconstitution
compares favorably with that observed in patients re-
ceiving unmanipulated DLI [5], in addition to being
associated with decreased levels of GVHD (Filicko
et al., manuscript submitted).
In conclusion, our results demonstrate that LLME
treatment of DLI can be associated with differing de-
grees of T cell repertoire complexity but overall does
not affect the complexity of either the CD8 or CD4
T cell repertoires; neither does it significantly affect
the overall posttransplantation repertoire reconstitu-
tion. In addition, after LLME treatment the remaining
T cells retain their ability to proliferate in response to
alloantigen stimulation. Taken together, these results
suggest that LLME might provide a more targeted
manipulation of the DLI, which is likely to afford ad-
vantages with regard to posttransplantation immune
reconstitution, mounting GVL effects, and diminish-
ing GVHD.
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